Testing a medication to prevent brain inflammation in lymphoma patients receiving immune cell therapy

Plain-English translation of NCT07892027 on ClinicalTrials.gov ↗ · Source last updated October 2026 · Translation generated November 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing to see if it can prevent a serious brain complication called ICANS that sometimes occurs in patients receiving CAR T-cell therapy for lymphoma. CAR T-cell therapy is a powerful cancer treatment, but it can cause inflammation in the brain and nerves as a side effect. This medication works by blocking immune cells from traveling to the fluid around your brain, which may help prevent this complication from developing.

Currently, when ICANS develops, doctors have to treat it with high-dose steroids, which can actually weaken the cancer-fighting effects of the CAR T-cell therapy. Researchers believe giving this medication before treatment starts might prevent the problem from occurring in the first place, allowing your immune therapy to work better.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with diffuse large B-cell lymphoma or mantle cell lymphoma that has either come back after responding to prior treatment or has not responded to treatment
you are eligible to receive CAR T-cell therapy according to your hospital's standards
you are in good enough general health to tolerate the treatment (ECOG performance status of 2 or better)
you are willing to use two forms of birth control for several months after receiving chemotherapy, if you are of childbearing age

You likely don't qualify if…

you have an active serious infection that is not being controlled by antibiotics or other treatments
you have a history of JC virus infection or active hepatitis B, hepatitis C, or HIV
you have active brain lymphoma or other serious brain or nervous system conditions such as recent stroke, seizures, dementia, or Parkinson's disease
you have ever been treated with natalizumab before, due to risk of your body developing antibodies against it
you are pregnant, nursing, or unwilling to use birth control as required

What participation looks like

You will receive chemotherapy ( and ) on two consecutive days to prepare your body. The day before your CAR T-cell infusion, you will receive an infusion of . Then on day zero, you will receive your CAR T-cell therapy infusion. Throughout the study, you will have regular blood tests, imaging scans (PET/CT), and follow-up visits to monitor how well the treatment is working and whether you develop any side effects, especially any signs of brain inflammation.

AI-generated summary from trial data · Nov 10, 2026 · Not medical advice

Testing a medication to prevent brain inflammation in lymphoma patients receiving immune cell therapy

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)